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CC chemokine receptors are expressed on hemato-
poetic cells, and these may impart selective homing
of monocyte, leukocyte, and lymphocyte subsets to
sites of in¯ammation. CC chemokine receptor 3 is
the major receptor on eosinophils and is also
expressed on other in¯ammatory cells suggesting its
important role for allergic diseases such as atopic
dermatitis and bronchial asthma. Eotaxin, eotaxin-2
and eotaxin-3 have been identi®ed as ligands that
only activate CC chemokine receptor 3. CC chemo-
kine receptor 3 is also activated by other promiscu-
ous ligands, however, such as RANTES and
monocyte chemotactic protein 4. To date, CC che-
mokine receptor 3 has not been reported to be
expressed on nonhematopoetic cells. In this study,
we investigated whether keratinocytes possess auto-
crine and paracrine mechanisms for CC chemokine
secretion and receptor expression as reported for the
expression of interleukin 8 and its receptors. Reverse
transcriptase polymerase chain reaction analysis
demonstrated that CC chemokine receptor 3 mRNA
is expressed constitutively in cultured keratinocytes.
The signal quantities of the CC chemokine receptor
3 amplicons showed lower intensities for keratino-
cytes than for eosinophils. In situ hybridization tech-
niques exhibited that basal cell layers of the
epidermis were stained homogeneously for CC
chemokine receptor 3 mRNA with a decreasing
signal to the upper epidermis showing that differenti-
ating and proliferating keratinocytes did express
mRNA speci®c for CC chemokine receptor 3.
Immunohistochemical studies con®rmed low expres-
sion of CC chemokine receptor 3 protein on epider-
mal keratinocytes compared to the high level
observed on in®ltrating eosinophils. Furthermore,
stimulation of cultured keratinocytes with eotaxin
resulted in an increased [3H]thymidine incorporation
indicating a role of CC chemokine receptor 3 in epi-
dermal proliferation and differentiation. These data
demonstrate that CC chemokine receptor 3 is
expressed not only on hematopoetic cells but also on
keratinocytes as nonhematopoetic cells with ecto-
dermal origin. Therefore, the identi®cation of CC
chemokine receptor 3 on epidermal keratinocytes
may indicate a role for CC chemokine receptor 3 and
its ligands in skin physiology and pathophysiology.
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C
hemokine receptors represent Gi-protein-coupled
seven transmembrane receptors that are divided into
four subgroups (C, CC, CXC, CX3C) according to
their ligands (Baggiolini, 1998; Luster, 1998). Each
member is a receptor for a unique set of one or more
CC chemokine agonists. Various CC chemokine receptors are
expressed on hematopoetic cells, and these may impart selective
homing of monocytes, leukocytes, and lymphocytes to sites of
in¯ammation. CCR3 is the major receptor on eosinophils (Kitaura
et al, 1996; Ponath et al, 1996a) and is also expressed on basophils
(Heath et al, 1997; Uguccioni et al, 1997) suggesting an important
role for allergic diseases such as atopic dermatitis and bronchial
asthma. Furthermore, CCR3 expression was observed on macro-
phages (Hariharan et al, 1999) and neural microglia cells (Albright et
al, 1999).
The CC chemokines eotaxin, eotaxin-2, and eotaxin-3 have
been identi®ed as ligands that exclusively activate the CCR3 and
seem to be monospeci®c (Elsner et al, 1996a; 1998; Ponath et al,
1996b; Forssmann et al, 1997; White et al, 1997). Other
chemokines recognize more than one chemokine receptor.
CCR3 is also activated by other promiscuous ligands, however,
such as RANTES, monocyte chemotactic protein 2 (MCP-2),
MCP-3, and MCP-4 (Alam et al, 1993; Dahinden et al, 1994; Kapp
et al, 1994; Petering et al, 1998).
Recent studies have shown that eotaxin, eotaxin-2, and eotaxin-
3 not only are able to induce chemotaxis but also stimulate the
release of reactive oxygen species and induce changes in relative F-
actin contents of human eosinophils as an indicator for locomotory-
associated cellular responses (Elsner et al, 1996a, 1998). Therefore,
eotaxin, eotaxin-2, and eotaxin-3 represent speci®c chemoattrac-
tants for certain hematopoetic cells. Furthermore, CXC chemo-
kines, e.g., interleukin-8 (IL-8), do not induce functional activity
even on activated human eosinophils indicating that CXCR1 and
CXCR2 are not expressed on the cell surface (Petering et al, 1999).
These ®ndings may suggest an important role for CCR3 and its
ligands in chronic in¯ammatory disorders.
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The ®nding that CCR3 is the principal receptor for eosinophil
responses to CC chemokines has led to the development of
monoclonal antibody (MoAb) 7B11 blocking CCR3 ligand
binding (Daugherty et al, 1996a; Heath et al, 1997; Elsner et al,
1998; Kitayama et al, 1998). In addition, CC chemokine receptor
directed antagonists such as Met-RANTES could be identi®ed.
Met-RANTES is principally described as a CCR1 antagonist, but
has also weak inhibitory properties on CCR3 (Proudfoot et al,
1996; Wells et al, 1996; Elsner et al, 1997).
To date, CCR3 has not been reported to be expressed on
nonhematopoetic cells, whereas CXC chemokine receptors exhibit
a broad distribution not only on hematopoetic cells but also on
endothelial cells, ®broblasts, and melanocytes (Holmes et al, 1991;
Murphy and Tiffany, 1991). Primary cultured human keratinocytes
are known to express mRNA speci®c for IL-8 as well as for the CC
chemokine eotaxin (Hein et al, 1997). Human keratinocytes are
known to synthesize and secret CXC chemokines, e.g., IL-8, and
can be stimulated by their own cytokine products. To investigate
whether human keratinocytes possess similar autocrine and
paracrine mechanisms for CC chemokine secretion and CC
chemokine receptor expression, reverse transcriptase polymerase
chain reaction (RT-PCR) analysis, in situ hybridization, and
receptor protein expression analysis were performed with cultured
human keratinocytes and skin biopsies. Tissue sections were
obtained from healthy individuals, patients with chronic in¯am-
matory diseases, and patients suffering from bullous pemphigoid.
This subepidermal blistering disease is characterized by a TH2-type
cytokine pattern as well as peripheral and tissue eosinophilia.
Therefore, in®ltrating eosinophils could be stained for CCR3 as a
positive control. In this study, we report that human keratinocytes
contain mRNA speci®c for the eotaxin receptor CCR3 and
express CCR3 protein. Functional data revealed that CCR3 may
play a role in epidermal proliferation and differentiation.
MATERIALS AND METHODS
Cell preparation
Human keratinocyte culture Normal human keratinocytes were obtained
from fresh trunk biopsies. Epidermal cells were disaggregated by
trypsinization (4°C, 12 h) in Hank's balanced salt solution without Ca2+
and Mg2+ containing 0.25% trypsin. The cells were plated out at 107
cells per 50 ml culture ¯ask in endotoxin-free keratinocyte growth
medium (KGM) containing 1.0 mM Ca2+ and incubated with 10% CO2
(37°C). Normal keratinocytes were derived from the second to fourth
passages grown as a monolayer to 80% con¯uence.
Isolation of human eosinophils Human eosinophils were isolated from
heparin-anticoagulated venous blood from normal nonatopic healthy
donors. The isolation was performed using Ficoll (Pharmacia) density
gradient centrifugation and eosinophils were puri®ed by negative
selection with anti-CD16 MoAb (clone 3G8, Immunotech, Hamburg,
Germany) coated Dynabeads M-450 (Dynal, Hamburg) as described
previously (Elsner et al, 1994). The resulting eosinophil purity
was > 99.5% as determined by ¯ow cytometric analysis (FACScan,
Becton Dickinson, Heidelberg, Germany) using phycoerythrin-
conjugated anti-CD16 MoAb (clone 3G8, Immunotech).
Chemokines, cytokines, and monoclonal antibodies Eotaxin was purchased
from Peprotech (London, U.K.). Bradykinin, epidermal growth factor
(EGF), and C5a were obtained from Sigma (Deisenhofen, Germany).
The anti-CCR3 MoAb 7B11 was derived from C57BL6 mice
immunized with CCR3 transfectants and prepared as described
previously (Daugherty et al, 1996; Heath et al, 1997). MoAb EG1 against
eosinophilic cationic protein (ECP) was received from Pharmacia
(Uppsala). The human IgG1 isotype control was obtained from Sigma.
CCR3 mRNA expression Total RNA was isolated from human
keratinocytes and eosinophils using the TRIzol kit (Gibco Life
Technologies, Karlsruhe, Germany) according to the manufacturer's
instructions based on the guanidine isothiocyanate method. First-strand
cDNA synthesis and PCR reaction were performed as described
previously (Elsner et al, 1996b; Petering et al, 1996, 1999). Primers for
the ampli®cation of CCR3 (sense, 5¢-GCCATTTCGGACCTGCT-
CTT-3¢; antisense, 5¢-TCCGCTCACAGTCATTTCCA-3¢) and b-actin
(sense, 5¢-GAGCGGGAAATCGTGCGTGACATT-3¢; antisense, 5¢-
GAAGGTAGTTTCGTGGATGCC-3¢) were designed according to the
published sequences (Accession No.: CCR3, AF026535; b-actin,
AB004047). PCR samples were run on a 1.8% agarose gel stained with
0.2 mg per ml ethidium bromide, and the PCR products were visualized
with ultraviolet light and photographed.
Automated sequencing of PCR products For automated sequencing
of PCR products, an Applied Biosystems Model 373 A (Forster City,
CA) was used. Nucleotide sequence data were analyzed with Lasergene
sequence analysis software (DNASTAR, Madison, WI).
CCR3 riboprobes and in situ hybridization RNA probes for CCR3
were designed from a plasmid constructed by cloning a 578 bp RT-
PCR fragment ampli®ed from human eosinophils into a polylinker site
of transcription vector pBluescript II SK± containing T3 and T7
polymerase recognition elements as described previously (Petering et al,
1996). After blunt-end ligation, the orientation and DNA sequence of
both insert strains were determined by cycle sequencing as described
above. Antisense (T3) and sense (T7) riboprobes were transcribed
enzymatically and digoxygenin-labeled according to the manufacturer's
instructions (Boehringer Mannheim, Germany). Probes were washed
twice by ethanol precipitation to remove unincorporated nucleotides and
stored in 10 nM dithiothreitol at ±80°C.
For in situ hybridization, tissue sections were ®xed with 4%
paraformaldehyde and washed with 1% phosphate-buffered saline (PBS).
Tissues were permeabilized with 50 mg per ml protease K (37°C,
30 min), washed once with 1% PBS, and incubated for 5 min with 2 3
standard saline citrate (SSC). The sections were dehydrated through
graded alcohol and air-dried. After prehybridization (55°C, 60 min) and
hybridization (55°C, 12 h) with standard hybridization solution (10%
dextran sulfate, 40% formamide, 4 3 SSC, 1 3 Denhard's, 10 mM
dithiothreitol, 100 mg per ml tRNA) slides were washed with SSC under
stringent conditions. Staining for CCR3 was carried out with
antidigoxygenin F(ab)¢ fragment conjugated to alkaline phosphatase at a
®nal dilution of 1:1000 according to the manufacturer's instructions
(Boehringer Mannheim). Slides stained with sense and antisense ribop-
robes were read blindly by two dermatopathologists.
Immunohistochemistry with human keratinocytes and
eosinophils Tissue sections were cut to 5 mm and adhered to silanized
slides. Immunostaining was performed (room temperature, 60 min) and
was developed by the avidin±biotin-peroxidase complex technique with
the chromogen fuchsin according to the manufacturer's
recommendations (DAKO). Staining for CCR3 protein was performed
with the anti-CCR3 MoAb 7b11 (750 mg per ml) at a ®nal dilution of
1:100 in 1% bovine serum albumin/PBS. Staining for eosinophil matrix
granular proteins was performed with MoAb EG1 speci®c for ECP
(Kiehl and Kapp, 1998). Non-reactive mouse antihuman antibodies of
IgG1 isotype were used as negative controls.
Immuno¯uorescence of cultured keratinocytes Immuno-
¯uorescence of cultured human trunk keratinocytes between the second
and fourth passages was performed using standard techniques. In brief,
keratinocytes were adjusted to a density of 1 3 107 cells per ml. Aliquots
(20 ml) containing 2 3 105 cells were incubated at 4°C for 30 min with
the indicated antibody or isotype control (IgG2). Thereafter, cells were
washed twice with 4°C PBS. For indirect immuno¯uorescence, cells
were stained in a second step by a ¯uorescein isothiocyanate (FITC)
conjugated mouse antihuman antibody (Immunotech) and subsequently
washed twice. Thereafter, cells were analyzed by ¯ow cytometry
(FACScan). The samples were excited at 488 nm and emission was
measured at 530 nm (FITC-labeled antibodies, ¯uorescence 1, green
¯uorescence). The CCR3 receptor expression was analyzed after
preincubation of cultured keratinocytes for 30 min at 37°C with the
CCR3 ligand eotaxin or medium alone. The mean channel ¯uorescence
of seven experiments was determined. Results were expressed as the
median ¯uorescence intensity after preincubation for 30 min versus the
median ¯uorescence intensity after incubation with medium. Incubation
of cells for longer than 30 min did not change the results.
Keratinocyte proliferation assay Keratinocytes were plated at
5 3 103 cells per well of a 96-well microtiter plate and cultured in
KGM for 5 d. The medium in each well was then replaced with KGM
supplemented with either EGF, IL-8, or eotaxin at the indicated
concentrations or KGM alone. Proliferation was measured by labeling six
replicate cultures with 0.5 mCi ml [3H]thymidine (Amersham,
Braunschweig, Germany) during a further 48 h of incubation. After
labeling, medium was removed, each well was washed with PBS, and
trichloroacetic acid (TCA) was added. The TCA-precipitated nucleic
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acid was solubilized in 100 ml of 0.1 M sodium hydroxide, 1% sodium
dodecyl sulfate, and 2% sodium carbonate for 30 min and the b decay
was counted in a liquid scintillation counter. The stimulation index was
de®ned by the ratio of mean counts per minute of stimulated to
unstimulated cultures.
RESULTS
Cultured human keratinocytes express mRNA speci®c for
CCR3 RT-PCR analysis was performed to investigate whether
human keratinocytes express mRNA speci®c for CCR3. For this
purpose, human trunk keratinocytes were cultured and passaged
two to four times prior to total RNA isolation. Using the primer
pairs indicated, DNA fragments with an expected size of 578 bp
speci®c for human CCR3 could be detected in cultured human
keratinocytes (Fig 1, lane 3). To clarify whether the ampli®ed PCR
products were speci®c for CCR3 and did not represent other
chemokine receptors, DNA sequence analysis was performed. PCR
products were sequenced automatically with vector-derived primer
pairs. Computer-aided nucleotide sequence analysis revealed that
all PCR products represent DNA sequences speci®c for CCR3
mRNA. As expected, highly puri®ed human eosinophils did
constitutively express CCR3 mRNA (Fig 1, lane 2). To
demonstrate that all mRNA preparations were highly puri®ed,
RT-PCR was performed simultaneously using primer pairs for b-
actin as standard (221 bp) (Fig 1). The signal quantities of the
CCR3 amplicons showed lower signal intensities for cultured
keratinocytes than for isolated human eosinophils. The results
indicate that CCR3 is expressed at mRNA level in cultured human
keratinocytes.
In situ hybridization studies reveal that CCR3 mRNA is
expressed in epidermal keratinocytes To investigate whether
CCR3 mRNA is not only expressed in vitro in cultured
keratinocytes but can also be detected in vivo in epidermal
keratinocytes, in situ hybridization studies were performed. Tissue
sections from ®ve patients suffering from bullous pemphigoid prior
to immunosuppressive therapy were studied for the expression of
CCR3 mRNA. Bullous pemphigoid represents a chronic
in¯ammatory autoimmune disease characterized by a local
accumulation of eosinophils with subsequent subepidermal blister
formation (Lever, 1979). Therefore, the colocalization of
keratinocytes and eosinophils in®ltrating the upper dermis and
epidermis allowed us to compare CCR3 signal speci®city and
intensity between different cells. Specimens were obtained from
perilesional and lesional skin and CCR3 mRNA expression was
analyzed by in situ hybridization. Strong CCR3 mRNA expression
was detected in in¯ammatory cells in®ltrating the upper dermis
(Fig 2A). Immunohistochemical staining with MoAb EG1
recognizing matrix granular proteins identi®ed these cells as
eosinophil granulocytes known to express CCR3 (Fig 2C). Like
eosinophils, basal cell layers of the epidermis were stained
homogeneously for CCR3 mRNA with a decreasing signal to
the upper epidermis showing that differentiating and proliferating
keratinocytes did express mRNA speci®c for CCR3 (Fig 2A).
Negative controls hybridized with sense RNA probes only showed
background signals (data not shown).
To investigate whether the expression of CCR3 mRNA in
keratinocytes is induced in the state of disease, specimens from
healthy volunteers were analyzed by in situ hybridization. As seen in
Fig 2(E), basal keratinocytes from normal individuals also showed
staining for CCR3 mRNA. A similar staining pattern could be
observed in tissue sections from chronic in¯ammatory diseases.
Figure 2(G) shows the expression of CCR3 mRNA in atopic
dermatitis, a T-cell-mediated disease affecting the upper dermis and
epidermis. Figure 2(H) demonstrates the expression of CCR3
mRNA in psoriasis vulgaris, a chronic in¯ammatory disease
characterized by epidermal hyperplasia and altered epidermal
differentiation. These data reveal that CCR3 mRNA is expressed
constitutively in human keratinocytes. The expression may not
depend on the state of activation of basal keratinocytes, e.g., in
disease affecting the basement membrane zone.
Immunohistochemical studies demonstrate that CCR3 is
expressed on epidermal keratinocytes To demonstrate that
the transcription of CCR3 mRNA is followed by the expression of
the receptor protein on the cell surface, bullous pemphigoid tissue
sections adjacent to those used for in situ hybridization were stained
immunohistochemically for CCR3. The colocalization of
keratinocytes and eosinophils allowed us again to compare the
signal quantities. Expression of CCR3 protein was observed on
epidermal keratinocytes with a marginally increased staining of the
basal cell layers (Fig 2B). Immunohistochemical staining of
specimens taken from healthy volunteers and patients suffering
from atopic dermatitis and psoriasis vulgaris exhibited a similar
staining pattern (data not shown). These results indicate that
proliferating and differentiating keratinocytes of the epidermis are
able to express CCR3 protein.
In comparison to human eosinophils in®ltrating the upper
dermis and epidermis, however, keratinocytes showed only a weak
CCR3 expression in terms of staining intensity indicating fewer
binding sites per cell (Fig 2B, D). Positive CCR3 staining of
eosinophils without immunohistochemical reaction on other
in®ltrating in¯ammatory cells, such as lymphocyte subpopulations,
demonstrated that anti-CCR3 MoAb 7B11 is also a speci®c marker
for CCR3 in immunohistochemical studies (Fig 2D).
Flow cytometry analysis reveals that CCR3 is expressed
heterogeneously on cultured keratinocytes To con®rm the
immunohistochemical data, the expression of CCR3 on cultured
human trunk keratinocytes was investigated by ¯ow cytometry.
Cells between the second and fourth passage were stained with the
anti-CCR3 MoAb 7B11 (Fig 3A).
Surprisingly, the expression of CCR3 on cultured keratinocytes
was donor dependent and differed between the healthy volunteers.
Cultured keratinocytes from two donors were negative or showed
only a weak staining for CCR3 in a small subpopulation of
keratinocytes (Fig 3B). Preincubation of cultured keratinocytes for
30 min with TH2-type cytokines (IL-4, IL-5) did not alter CCR3
expression (data not shown). To demonstrate whether the anti-
CCR3 MoAb 7B11 binds speci®cally to CCR3, cultured human
keratinocytes were incubated for 30 min with eotaxin at a
concentration of 125.0 nM or medium. As expected, preincuba-
tion of cultured keratinocytes with eotaxin induced downregula-
tion of CCR3 on the cell surface, indicating that the CCR3 ligand
eotaxin was able to bind speci®cally to its receptor expressed on
keratinocytes (Fig 3A).
Figure 1. CCR3 mRNA is expressed in cultured human
keratinocytes. mRNA from cultured human keratinocytes and puri®ed
eosinophils was isolated and ®rst-strand cDNA synthesis was performed.
PCR was carried out with primer pairs speci®c for CCR3 (expected size
578 bp) and b-actin (expected size 221 bp) as an internal standard. The
amplicons were separated by electrophoresis in 1.8% agarose gel and
stained by ethidium bromide. Lane 1, 50 bp DNA size marker; lane 2,
human eosinophil mRNA; lane 3, human keratinocyte mRNA. One
representative experiment out of four is shown.
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Proliferation of cultured human keratinocytes after
stimulation with eotaxin can be inhibited by anti-
CCR3 Previous studies have shown that eotaxin is expressed in
tissue specimens obtained from chronic in¯ammatory lesions
(Rothenberg et al, 1995). These ®ndings prompted us to
investigate whether eotaxin may have any functional effects on
epidermal keratinocytes, e.g., cell proliferation and differentiation.
Cultured human epidermal keratinocytes were stimulated with
eotaxin (10±1000 nM) and the incorporation of [3H]thymidine was
detected as a marker for cell proliferation. As seen in Fig 4, eotaxin
induced dose-dependently a proliferation of human keratinocytes.
In this experiment, eotaxin was as effective as IL-8 with a
maximum of cell proliferation at a concentration of 100 nM
(Fig 4). In addition, proliferation of cultured human keratinocytes
was also induced by other CCR3 ligands such as RANTES and
MCP-4 representing two other potent activators of CCR3. At
equivalent concentrations eotaxin seemed to be more effective than
RANTES or MCP-4, however (Fig 4). EGF used as a positive
control was more potent than eotaxin at concentrations above
1 mM. Moreover, whereas EGF induced a dose-related curve all
Figure 2. In situ hybridization and
immunohistochemical analysis for CCR3
mRNA and protein expression on human
keratinocytes. (A) In tissue sections from patients
with bullous pemphigoid CCR3 mRNA
expression was analyzed by in situ hybridization.
Basal cell layers of the epidermis were
homogeneously stained for CCR3 mRNA with a
decreasing intensity to the upper epidermis.
Strong CCR3 mRNA expression was detected in
in¯ammatory cells in®ltrating the upper dermis.
(B) Immunohistochemistry with anti-CCR3
MoAb 7B11 revealed that CCR3 protein is
expressed on epidermal keratinocytes. (C)
Immunohistochemical staining with MoAb EG1
recognizing ECP identi®ed in¯ammatory cells as
human eosinophils. (D) Human eosinophils
in®ltrating the upper dermis showed more intense
immunohistochemical staining for CCR3 than
epidermal keratinocytes indicating more binding
sites per cell. (E) In situ hybridization revealed that
basal keratinocytes from normal individuals also
showed staining for CCR3 mRNA. A similar
staining pattern could be observed in chronic
in¯ammatory diseases: (F) expression of CCR3
mRNA in bullous pemphigoid; (G) expression of
CCR3 mRNA in atopic dermatitis; (H)
expression of CCR3 mRNA in psoriasis vulgaris.
Scale bars: (A) 100 mm; (B±D) 50 mm.
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chemokines tested induced a bell-shaped curve with respect to
incorporation of [3H]thymidine in epidermal keratinocytes.
To investigate whether the eotaxin-induced proliferation of
keratinocytes was mediated via CCR3, cultured keratinocytes were
preincubated with anti-CCR3 MoAb 7B11. As demonstrated
previously, this antibody is able to block eotaxin binding to CCR3
completely and inhibits CCR3-speci®c cell activation as demon-
strated previously (Daugherty et al, 1996a; Heath et al, 1997; Elsner
et al, 1998). As seen in Fig 4 preincubation of keratinocytes with
the anti-CCR3 MoAb 7B11 inhibited the proliferation of
keratinocytes induced by eotaxin. This experiment demonstrates
that the proliferation of keratinocytes after stimulation with eotaxin
can be inhibited by antagonizing CCR3-mediated effects.
DISCUSSION
Chemokines are proin¯ammatory cytokines known to be involved
in chronic in¯ammatory diseases such as atopic dermatitis and
allergic asthma (Baggiolini, 1998; Luster, 1998). Recent studies
have shown that the CC chemokine eotaxin is elevated in the
bronchial mucosa of asthmatic patients and is expressed by epithelial
and endothelial cells (Ying et al, 1997). CCR3 was identi®ed
independently by two different groups as the eotaxin receptor on
human eosinophils (Daugherty et al, 1996; Ponath et al, 1996a) and
further studies showed the expression of CCR3 also on basophils
suggesting that this chemokine receptor may play a central role in
chronic in¯ammatory disorders (Kitaura et al, 1996; Ponath et al,
1996b; Uguccioni et al, 1997). So far, CCR3 has only been
identi®ed on hematopoetic cells whereas CXC chemokine
receptors are also expressed on nonhematopoetic cells such as
®broblasts, melanocytes, and keratinocytes (Holmes et al, 1991;
Murphy et al, 1991; Norgauer et al, 1996). In psoriatic skin,
characterized by epidermal hyperplasia and altered epidermal
differentiation, IL-8 receptors were found to be expressed at high
levels (Schulz et al, 1993; Kulke et al, 1998). In vitro studies
con®rmed that keratinocyte migration and growth can be stimu-
lated by its ligand IL-8 (Tuschil et al, 1992). As endothelial and
epithelial cells of the lung and also epidermal keratinocytes are
known to produce CXC chemokines such as IL-8 (Sica et al, 1990;
Gillitzer et al, 1991; Huber et al, 1991), autocrine and paracrine
mechanisms seem to be responsible for proliferation and differen-
tiation of nonhematopoetic cells.
Recently, increased levels of CC chemokine eotaxin have been
found in respiratory epithelium and endothelium as well as in the
intestinal mucosa (Garcia-Zepeda et al, 1996; Matthews et al, 1998).
Hein et al detected eotaxin mRNA at low levels in stimulated
primary keratinocytes (Hein et al, 1997). Therefore, it is tempting
to speculate that human keratinocytes also possess autocrine and
paracrine mechanisms for CC chemokine secretion and CC
Figure 3. Flow cytometry analysis reveals that CCR3 is expressed
heterogeneously on cultured keratinocytes. Overlay histogram for
the expression of CCR3 on cultured human trunk keratinocytes. Cells
between the second and fourth passage were stained for CCR3 with the
anti-CCR3 MoAb 7B11. (A) The bold line represents cultured
keratinocytes expressing CCR3. The dotted line indicates cultured
keratinocytes preincubated with 125.0 nM eotaxin for 30 min showing a
downregulation of the CCR3. The thin line represents the IgG2a isotype
control. These data demonstrate that eotaxin was able to bind speci®cally
to CCR3 expressed on human keratinocytes. (B) The expression of
CCR3 was donor dependent and differed between healthy volunteers. In
two donors cultured keratinocytes appeared negative or showed only a
weak staining for CCR3 in a small subpopulation of keratinocytes as
demonstrated by the bold line.
Figure 4. Proliferation of cultured human keratinocytes after
stimulation with eotaxin can be inhibited by anti-CCR3 MoAb
7B11. Cultured human keratinocytes were stimulated with CC
chemokines eotaxin, MCP-4, RANTES, and IL-8 as well as EGF in
different concentrations (10±1000 nM). The incorporation of
[3H]thymidine was detected as a marker for cell proliferation. Data are
expressed as proliferation index (stimuli-induced [3H]thymidine
incorporation/medium-induced [3H]thymidine incorporation). In one
experiment keratinocytes were preincubated with the anti-CCR3 MoAb
7B11 and subsequently stimulated with eotaxin (10±7 M). One
representative experiment out of four is shown indicating that eotaxin
induces proliferation of human keratinocytes.
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chemokine receptor expression similar to their CXC counterpart.
This study describes the functional analysis and expression of the
predominant eosinophil CC chemokine receptor CCR3 on human
keratinocytes in vitro in comparison to isolated eosinophils and
in vivo to eosinophils in®ltrating the upper dermis and epidermis.
In the ®rst set of experiments, RT-PCR analysis was performed
demonstrating that cultured human keratinocytes constitutively
express CCR3 mRNA. Signal quantities of CCR3 amplicons
showed lower signal intensities for keratinocytes than for isolated
eosinophils. To rule out that the RT-PCR products were due to a
false-positive ampli®cation of other chemokine receptors, e.g.,
CXCR1 or CXCR2, nucleotide sequence analysis of the
amplicons was performed and revealed a DNA sequence homolog
to published CCR3 mRNA sequences. To con®rm that CCR3
mRNA expression was also observed in vivo, skin biopsies were
analyzed for CCR3 mRNA by in situ hybridization techniques.
Again, CCR3 mRNA could be detected and was predominantly
expressed in basal keratinocytes whereas in the upper cell layers the
receptor expression was decreased. To investigate whether the
expression of CCR3 mRNA is induced in the state of disease, skin
biopsies from healthy volunteers and patients suffering from
different in¯ammatory diseases (atopic dermatitis, psoriasis vulgaris,
and bullous pemphigoid) were analyzed. Our data revealed that
CCR3 mRNA is constitutively expressed on epidermal keratino-
cytes and may not depend on the state of cell activation. The
®nding that CCR3 mRNA is constitutively expressed on
keratinocytes obtained from different in¯ammatory diseases affect-
ing the epidermis (psoriasis vulgaris), basal membrane (bullous
pemphigoid), and epidermis as well as the upper dermis (atopic
dermatitis) suggests that the low level of CCR3 mRNA expression
may not have a pathophysiologic role in these disorders. Our results
indicate that in particular proliferating and differentiating kerati-
nocytes of the basal stratum express CCR3 mRNA. This study
provides evidence that CCR3 mRNA is not only expressed on
in¯ammatory cells derived from hematopoetic precursors but can
also be expressed on human keratinocytes as nonhematopoetic cells
with ectodermal origin.
The expression of CCR3 protein on keratinocytes was inves-
tigated by immunohistochemical staining for CCR3 with tissue
sections adjacent to those used for in situ hybridization. The
experiments indicated that CCR3 protein is expressed in human
epidermis. Immunohistochemistry was performed with tissue
sections from patients with bullous pemphigoid, a blistering
autoimmune disease characterized by an excessive synthesis of
proin¯ammatory cytokines. TH2-type cytokines such as IL-4 and
IL-5 but also CC chemokines, e.g., RANTES, have been
identi®ed in the skin and the blister ¯uid of these patients and
contribute to the epidermal and dermal in®ltration of eosinophils
(D'Auria et al, 1998; Inaoki and Takehara, 1998). IL-4 and IL-5
may upregulate the expression of CCR3 on in¯ammatory cells and
may also increase CCR3 protein synthesis in epidermal keratino-
cytes (Tiffany et al, 1998; Jinquan et al, 1999). Therefore, it was
obvious to speculate that cytokine priming of keratinocytes in vivo
may contribute to the expression of CCR3 protein. In our in vitro
experiments, however, no difference in CCR3 expression could be
observed after preincubation of cultured keratinocytes with TH2-
type cytokines. The colocalization of keratinocytes and eosinophils
in®ltrating the upper dermis and epidermis in skin biopsies from
bullous pemphigoid allowed us to compare CCR3 signal speci®city
and intensity between different cells indicating that human
keratinocytes possess fewer binding sites per cell than human
eosinophils.
To con®rm these immunohistochemical ®ndings ¯ow cytometry
analysis was performed demonstrating an inhomogeneous expres-
sion of CCR3 on cultured keratinocytes, whereas CCR3 mRNA
was expressed constitutively indicating a receptor regulation at the
post-transcriptional level. The CCR3 expression on the cell surface
was donor dependent and differed between our healthy volunteers.
Moreover, we could clearly demonstrate that preincubation of
CCR3+ keratinocytes with eotaxin resulted in a downregulation of
CCR3, which has recently been shown in eosinophils (Elsner et al,
2000). Preincubation of keratinocytes with TH2-type cytokines
did not alter CCR3 receptor expression.
Recent studies have shown that the CXC chemokine IL-8 exerts
a direct in¯uence on several keratinocyte functions including
epidermal proliferation and differentiation (Kapp, 1993).
Furthermore, in psoriatic skin, IL-8 and the growth-related
oncogen a, another ligand for CXCR2, are produced by lesional
keratinocytes especially from the upper epidermal cell layers (Larsen
et al, 1989) as part of an autocrine and paracrine cytokine network.
The CC chemokine eotaxin can also be synthesized and released by
keratinocytes and therefore not only may contribute to the local
accumulation of eosinophils and TH2-type lymphocytes but also
may modulate the differentiation and proliferation of keratinocytes
similar to IL-8 (Hein et al, 1997). To investigate whether such
autocrine and paracrine mechanisms exist for CC chemokines,
growth-promoting activities of eotaxin on cultured keratinocytes
were analyzed. Our data suggest that eotaxin represents a weak
stimulus for proliferation of human keratinocytes. The observation
that keratinocyte proliferation and differentiation was also induced
by RANTES and MCP-4, two other potent activators of CCR3,
suggests that the effect of eotaxin may be due to CCR3 binding
and signaling. Interestingly, all of the CCR3 ligands tested induced
a bell-shaped curve with regard to keratinocyte proliferation. As we
could clearly demonstrate that eotaxin was able to induce a
downregulation of CCR3 in CCR3+ keratinocytes it could be
speculated that CCR3 ligands downregulate CCR3 at a concen-
tration of 10±7 M. Thus, the reduced proliferation index of
keratinocytes in response to a higher concentration (10±6 M) of
CCR3 ligands could be explained by a downregulation of CCR3.
To further prove this hypothesis, cultured keratinocytes were
preincubated with anti-CCR3 MoAb 7B11 known to speci®cally
block the activation of human eosinophils by CCR3 ligands (Heath
et al, 1997; Elsner et al, 1998; Kitayama et al, 1998). The anti-
CCR3 MoAb 7B11 was able to inhibit eotaxin-induced prolifer-
ation of keratinocytes indicating that binding to CCR3 is the initial
step of the observed keratinocyte differentiation and proliferation.
In summary, these data provide evidence that CCR3 is expressed
not only on hematopoetic cells but also on human keratinocytes as
nonhematopoetic cells with ectodermal origin. The level of
receptor expression is donor dependent. In addition to its
involvement in chemotaxis and activation of the respiratory burst
of human eosinophils eotaxin and other CCR3 ligands may
contribute to local wound repair and healing mechanisms inte-
grating different ways of tissue reconstitution. Therefore, the
identi®cation of CCR3 on epidermal keratinocytes suggests that
CCR3 and its ligands, especially eotaxin, may play an important
role in skin physiology and pathophysiology.
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